JP2017526368A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017526368A5 JP2017526368A5 JP2017511675A JP2017511675A JP2017526368A5 JP 2017526368 A5 JP2017526368 A5 JP 2017526368A5 JP 2017511675 A JP2017511675 A JP 2017511675A JP 2017511675 A JP2017511675 A JP 2017511675A JP 2017526368 A5 JP2017526368 A5 JP 2017526368A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- kynureninase
- enzyme
- composition
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 36
- 210000004027 cell Anatomy 0.000 claims description 33
- 102200155474 rs397507512 Human genes 0.000 claims description 28
- 206010028980 Neoplasm Diseases 0.000 claims description 20
- 102000004190 Enzymes Human genes 0.000 claims description 19
- 108090000790 Enzymes Proteins 0.000 claims description 19
- 108010031676 Kynureninase Proteins 0.000 claims description 18
- 102000005447 kynureninase Human genes 0.000 claims description 18
- 238000009472 formulation Methods 0.000 claims description 15
- 102200011638 rs587777189 Human genes 0.000 claims description 15
- 108020004707 nucleic acids Proteins 0.000 claims description 14
- 102000039446 nucleic acids Human genes 0.000 claims description 14
- 150000007523 nucleic acids Chemical class 0.000 claims description 14
- 239000002202 Polyethylene glycol Substances 0.000 claims description 12
- 102220350170 c.295G>T Human genes 0.000 claims description 12
- 229920001223 polyethylene glycol Polymers 0.000 claims description 12
- 230000009261 transgenic effect Effects 0.000 claims description 9
- 101001021858 Homo sapiens Kynureninase Proteins 0.000 claims description 8
- 238000006467 substitution reaction Methods 0.000 claims description 8
- 241000238631 Hexapoda Species 0.000 claims description 6
- 239000000427 antigen Substances 0.000 claims description 6
- 102000036639 antigens Human genes 0.000 claims description 6
- 108091007433 antigens Proteins 0.000 claims description 6
- 241000894006 Bacteria Species 0.000 claims description 4
- 108020004705 Codon Proteins 0.000 claims description 4
- 241000233866 Fungi Species 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 4
- 230000001093 anti-cancer Effects 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 239000013604 expression vector Substances 0.000 claims description 4
- 238000001802 infusion Methods 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 102220020916 rs80357276 Human genes 0.000 claims description 4
- 102220392946 rs181428774 Human genes 0.000 claims description 3
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 2
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 2
- 101001037256 Homo sapiens Indoleamine 2,3-dioxygenase 1 Proteins 0.000 claims description 2
- 101001037261 Homo sapiens Indoleamine 2,3-dioxygenase 2 Proteins 0.000 claims description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 2
- 102100040061 Indoleamine 2,3-dioxygenase 1 Human genes 0.000 claims description 2
- 102100040062 Indoleamine 2,3-dioxygenase 2 Human genes 0.000 claims description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 2
- 108091008874 T cell receptors Proteins 0.000 claims description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 2
- 102100040653 Tryptophan 2,3-dioxygenase Human genes 0.000 claims description 2
- 101710136122 Tryptophan 2,3-dioxygenase Proteins 0.000 claims description 2
- 230000001580 bacterial effect Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000002538 fungal effect Effects 0.000 claims description 2
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000001361 intraarterial administration Methods 0.000 claims description 2
- 238000007917 intracranial administration Methods 0.000 claims description 2
- 238000007912 intraperitoneal administration Methods 0.000 claims description 2
- 230000002601 intratumoral effect Effects 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 230000002262 irrigation Effects 0.000 claims description 2
- 238000003973 irrigation Methods 0.000 claims description 2
- 210000004962 mammalian cell Anatomy 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 210000004400 mucous membrane Anatomy 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 230000010412 perfusion Effects 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 241000894007 species Species 0.000 claims description 2
- 238000000034 method Methods 0.000 description 4
- 230000005867 T cell response Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462043663P | 2014-08-29 | 2014-08-29 | |
| US62/043,663 | 2014-08-29 | ||
| US201562120418P | 2015-02-25 | 2015-02-25 | |
| US62/120,418 | 2015-02-25 | ||
| PCT/US2015/047475 WO2016033488A1 (en) | 2014-08-29 | 2015-08-28 | Administration of kynurenine depleting enzymes for tumor therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020159230A Division JP2021006046A (ja) | 2014-08-29 | 2020-09-24 | 腫瘍の治療のための、キヌレニンを枯渇させる酵素の投与 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017526368A JP2017526368A (ja) | 2017-09-14 |
| JP2017526368A5 true JP2017526368A5 (enExample) | 2018-10-04 |
| JP7080053B2 JP7080053B2 (ja) | 2022-06-03 |
Family
ID=55400679
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017511675A Active JP7080053B2 (ja) | 2014-08-29 | 2015-08-28 | 腫瘍の治療のための、キヌレニンを枯渇させる酵素の投与 |
| JP2020159230A Pending JP2021006046A (ja) | 2014-08-29 | 2020-09-24 | 腫瘍の治療のための、キヌレニンを枯渇させる酵素の投与 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020159230A Pending JP2021006046A (ja) | 2014-08-29 | 2020-09-24 | 腫瘍の治療のための、キヌレニンを枯渇させる酵素の投与 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US9975959B2 (enExample) |
| EP (1) | EP3186371B1 (enExample) |
| JP (2) | JP7080053B2 (enExample) |
| CA (1) | CA2959508A1 (enExample) |
| ES (1) | ES2987380T3 (enExample) |
| IL (1) | IL250833B (enExample) |
| WO (1) | WO2016033488A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3492094A1 (en) | 2013-08-30 | 2019-06-05 | Board of Regents, The University of Texas System | Administration of kynurenine depleting enzymes for tumor therapy |
| EP3186371B1 (en) | 2014-08-29 | 2024-08-14 | Board of Regents, The University of Texas System | Administration of kynurenine depleting enzymes for tumor therapy |
| US11723932B2 (en) | 2016-01-11 | 2023-08-15 | Synlogic Operating Company, Inc. | Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells |
| WO2017136795A1 (en) | 2016-02-04 | 2017-08-10 | Synlogic, Inc. | Bacteria engineered to treat diseases associated with tryptophan metabolism |
| WO2017151860A1 (en) * | 2016-03-02 | 2017-09-08 | Broard Of Regents, The University Of Texas System | Human kynureninase enzyme variants having improved pharmacological properties |
| KR20190084053A (ko) * | 2016-10-13 | 2019-07-15 | 주노 쎄러퓨티크스 인코퍼레이티드 | 트립토판 대사 경로 조절인자 관련 면역 치료 방법 및 조성물 |
| AU2018205276A1 (en) | 2017-01-06 | 2019-07-18 | Synlogic Operating Company, Inc. | Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells |
| JP7432851B2 (ja) * | 2018-04-16 | 2024-02-19 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | ヒトキヌレニナーゼ酵素及びその使用 |
| WO2021076966A1 (en) * | 2019-10-17 | 2021-04-22 | Ikena Oncology, Inc. | Pegylated kynureninase enzymes and uses thereof for the treatment of cancer |
| WO2022154107A1 (ja) | 2021-01-18 | 2022-07-21 | イビデン株式会社 | 組電池用熱伝達抑制シート及び組電池 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA154754A (en) | 1912-06-19 | 1914-03-31 | Henry Blanford | Can filling and sealing machine |
| US5824311A (en) | 1987-11-30 | 1998-10-20 | Trustees Of The University Of Pennsylvania | Treatment of tumors with monoclonal antibodies against oncogene antigens |
| US4870287A (en) | 1988-03-03 | 1989-09-26 | Loma Linda University Medical Center | Multi-station proton beam therapy system |
| US5329028A (en) | 1992-08-05 | 1994-07-12 | Genentech, Inc. | Carbohydrate-directed cross-linking reagents |
| US5846945A (en) | 1993-02-16 | 1998-12-08 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
| US5801005A (en) | 1993-03-17 | 1998-09-01 | University Of Washington | Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated |
| GB9506466D0 (en) | 1994-08-26 | 1995-05-17 | Prolifix Ltd | Cell cycle regulated repressor and dna element |
| US5760395A (en) | 1996-04-18 | 1998-06-02 | Universities Research Assoc., Inc. | Method and apparatus for laser-controlled proton beam radiology |
| US5739169A (en) | 1996-05-31 | 1998-04-14 | Procept, Incorporated | Aromatic compounds for inhibiting immune response |
| CN1330774C (zh) | 2002-03-01 | 2007-08-08 | 国家人类基因组南方研究中心 | 犬尿氨酸水解酶多态性及其用途 |
| CA2520586C (en) | 2003-03-27 | 2011-06-14 | Lankenau Institute For Medical Research | Novel ido inhibitors and methods of use |
| US20070207158A1 (en) | 2003-06-17 | 2007-09-06 | Harrison Roger G | Conjugate for the specific targeting of anticancer agents to tumor cells or tumor vasculature and production thereof |
| EP1648512A4 (en) | 2003-07-31 | 2009-01-21 | Immunomedics Inc | ANTI-CD19 ANTIBODIES |
| JP2008237022A (ja) | 2005-06-30 | 2008-10-09 | Osaka Prefecture | 非小細胞肺がんの予防・治療剤および診断薬 |
| JP5319532B2 (ja) | 2006-09-19 | 2013-10-16 | インサイト・コーポレイション | インドールアミン２，３−ジオキシゲナーゼのモジュレーターとしてのｎ−ヒドロキシアミジノヘテロサイクル |
| EP2483301A1 (en) | 2009-10-01 | 2012-08-08 | The United States Of America, As Represented By The Secretary, Department of Health and Human Services | Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer |
| US9212229B2 (en) | 2010-09-08 | 2015-12-15 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Chimeric antigen receptors with an optimized hinge region |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| WO2012099441A2 (ko) | 2011-01-21 | 2012-07-26 | 인제대학교산학협력단 | 트립토판 대사효소 유전자를 발현하는 줄기세포를 함유하는 면역 반응 억제용 조성물 |
| KR20120085209A (ko) | 2011-01-21 | 2012-07-31 | 인제대학교 산학협력단 | 트립토판 대사효소 유전자를 발현하는 줄기세포를 함유하는 면역 반응 억제용 조성물 |
| US9593062B2 (en) | 2011-09-07 | 2017-03-14 | Deutschland Krebsforschungszentrum | Means and methods for treating and/or preventing natural AHR ligand-dependent cancer |
| WO2013059593A1 (en) | 2011-10-20 | 2013-04-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-cd22 chimeric antigen receptors |
| EP3492094A1 (en) | 2013-08-30 | 2019-06-05 | Board of Regents, The University of Texas System | Administration of kynurenine depleting enzymes for tumor therapy |
| CN104660565B (zh) * | 2013-11-22 | 2018-07-20 | 华为技术有限公司 | 恶意攻击的检测方法和装置 |
| EP3186371B1 (en) | 2014-08-29 | 2024-08-14 | Board of Regents, The University of Texas System | Administration of kynurenine depleting enzymes for tumor therapy |
| WO2017151860A1 (en) | 2016-03-02 | 2017-09-08 | Broard Of Regents, The University Of Texas System | Human kynureninase enzyme variants having improved pharmacological properties |
| JP7432851B2 (ja) * | 2018-04-16 | 2024-02-19 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | ヒトキヌレニナーゼ酵素及びその使用 |
-
2015
- 2015-08-28 EP EP15834988.6A patent/EP3186371B1/en active Active
- 2015-08-28 ES ES15834988T patent/ES2987380T3/es active Active
- 2015-08-28 US US14/839,293 patent/US9975959B2/en active Active
- 2015-08-28 JP JP2017511675A patent/JP7080053B2/ja active Active
- 2015-08-28 WO PCT/US2015/047475 patent/WO2016033488A1/en not_active Ceased
- 2015-08-28 CA CA2959508A patent/CA2959508A1/en active Pending
- 2015-08-28 IL IL250833A patent/IL250833B/en unknown
-
2018
- 2018-04-25 US US15/961,968 patent/US11168142B2/en active Active
-
2020
- 2020-09-24 JP JP2020159230A patent/JP2021006046A/ja active Pending
-
2021
- 2021-10-11 US US17/498,520 patent/US20220275099A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017526368A5 (enExample) | ||
| ES2759248T3 (es) | Constructos de anticuerpo para CDH19 y CD3 | |
| US10995144B2 (en) | Methods of detecting a solid tumor with anti-IL1RAP antibodies | |
| CN108473572B (zh) | 用于治疗血源性癌症的免疫检查点抑制剂 | |
| ES2818229T3 (es) | Formulación anti-IFNAR1 estable | |
| ES2986360T3 (es) | Proteínas de unión a antígeno que se unen a PD-L1 | |
| ES2882157T3 (es) | Productos terapéuticos de anticuerpos que se unen a CTLA4 | |
| CN114380912B (zh) | 结合cd47的抗体治疗剂 | |
| JP2016533753A5 (enExample) | ||
| JPWO2020138489A1 (ja) | 新規抗ｃｃｒ８抗体 | |
| UA124254C2 (uk) | Біспецифічна антигензв'язувальна молекула, яка активує t-клітини | |
| US12252746B2 (en) | Anti-CD46 antibodies and methods of use | |
| JP2018531215A6 (ja) | 血液由来のがんの治療における使用を目的とする免疫チェックポイント阻害物質 | |
| UA114883C2 (uk) | Антитіло до рецептора епідермального фактора росту-3 (her3) | |
| ES2930681T3 (es) | Linfocitos T transfectados y receptores de linfocito T para el uso en la inmunoterapia contra el cáncer | |
| KR20150036700A (ko) | Cd22에 대해 특이적인 항체 및 이들의 사용 방법 | |
| WO2016112855A1 (zh) | 抗cd19单克隆抗体及其制备方法 | |
| JP2010526528A (ja) | 補体因子ｈ由来ショートコンセンサスリピート−抗体構築物 | |
| US20230331804A1 (en) | Nanoparticle systems to stimulate and maintain immune system responsiveness at treatment sites | |
| US12161720B2 (en) | Cell assembly-mediated delivery of checkpoint inhibitors for cancer immunotherapy | |
| CN109748968A (zh) | Bcma特异性嵌合抗原受体t细胞及其应用 | |
| KR20230084478A (ko) | 면역원성 코로나 바이러스 융합 단백질 및 관련 방법 | |
| CN113194925A (zh) | 抗体制剂 | |
| UA129953C2 (uk) | АНТИТІЛО ПРОТИ Sema3A ТА ЙОГО ЗАСТОСУВАННЯ ДЛЯ ЛІКУВАННЯ ЗАХВОРЮВАННЯ ОЧЕЙ | |
| CN108794624A (zh) | 抗h7n9流感病毒的中和性单克隆抗体 |